Researchers find common drug could halt coronavirus replicat
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A drug commonly used to treat stomach ulcers has shown promise in preventing the Sars-CoV-2 coronavirus from replicating in an animal model, a study by led by University of Hong Kong (HKU) scientists and published in Nature Microbiology has found.

Key findings:

• Ranitidine bismuth citrate (RBC), could achieve similar outcomes to the coronavirus drug remdesivir, but at a lower cost.

• In a hamster model, RBC was able to reduce viral loads to just one-hundredth of their previous levels in both the upper and lower respiratory tracts, and to mitigate virus-associated pneumonia.

• RBC can target vital non-structural protein 13 (Nsp13), a viral helicase that is essential for Sars-CoV-2 to replicate.

• Helicase acted like scissors in the unwinding process of DNA, leaving the resulting single-stranded DNA to serve as a template for the virus to be copied.

• RBC and its bismuth compounds, however, kick out the zinc ions in the zinc-binding domain of the helicase, making it dysfunctional and unable to unwind DNA.

• Once the helicase doesn’t work, the virus will lose its ability to replicate or multiply.

• It can be used in the form of drug cocktails that target multiple areas so it is harder for the virus to build resistance.

Read the complete study here:

Dr. S●●●●●●i P●●l and 32 others like this26 shares
Dr. P●●●●●●●●h S●●h
Dr. P●●●●●●●●h S●●h Pathology
One really interesting aspect of medical practice is the off-label uses of drug backed by some pharmacological rationale. Drugs have various synergistic, additive, antagonistic actions and serendipitous use denoting "repurposability" in a newer disease. What this signifies is a cluster of molecular targets drugs act on not just on the intended ones. It essentially means the researching scientists and drug developers mustn' t ignore the adverse drug reactions (ADRs) as something of no benefit to science. If we look into potentialities, these ADRs could really be game-changers!... Read more
Oct 12, 2020Like13
Dr. I●●●●●●E G●●●A
Dr. I●●●●●●E G●●●A Plastic Surgery
Wasn' t the drug banned though?
Oct 13, 2020Like2